May 21, 2022
Oritinib demonstrated almost complete disease control in previously treated patients with EGFR T790M–mutant, locally advanced or metastatic non–small cell lung cancer.
May 18, 2022
During a live virtual event, Anne S. Tsao, MD, discussed the choice of targeted therapy for a patient with non–small cell lung cancer with an EGFR exon 20 insertion.
May 13, 2022
Results of a phase 1 study of a fourth-generation EGFR tyrosine kinase inhibitor will be presented at the International Association for the Study of Lung Cancer 2022 World Conference.
May 11, 2022
Andreas Saltos, MD, discusses a phase 1 trial of binimetinib and erlotinib for patients with non–small cell lung cancer and EGFR or KRAS mutations.
April 15, 2022
Aparna Hegde, MD, discusses the decision to use osimertinib as soon as possible in patients with EGFR-positive non–small cell lung cancer.
April 14, 2022
Danny Nguyen, MD, discusses next steps for research of mobocertinib in patients with EGFR-positive non–small cell lung cancer.
April 11, 2022
During a live virtual event, Matthew A. Gubens, MD, MS, and participants discussed their reactions to the ADAURA trial of osimertinib for patients with EGFR-positive non–small cell lung cancer.
April 03, 2022
Ravi Salgia, MD, explains how treatment with a tyrosine kinase inhibitor in patients with non–small cell lung cancer can lead to disease transformation.
March 15, 2022
In a subgroup analysis of patients with non-small cell lung cancer who have EGFR sensitizing mutations, the regimen of atezolizumab plus bevacizumab plus carboplatin, and paclitaxel, had a stonger survival benefit compared to other therapies.
March 14, 2022
During a live virtual event, Matthew A. Gubens, MD, MS, discussed adjuvant chemotherapy using carboplatin or cisplatin in patients with EGFR-positive non–small cell lung cancer.